Circulating pentraxin 3 in severe COVID-19 or other pulmonary sepsis

Eur J Clin Invest. 2021 May;51(5):e13530. doi: 10.1111/eci.13530. Epub 2021 Mar 13.

Alessandro Protti^{1

2}, Jennifer Meessen³, Barbara Bottazzi⁴, Cecilia Garlanda^{2

4}, Angelo Milani⁵, Monica Bacci⁶, Alberto Mantovani^{2

4

7}, Maurizio Cecconi^{1

2}, Roberto Latini³, Pietro Caironi^{8

9}

¹ Department of Anaesthesia and Intensive Care Units, Humanitas Clinical and Research Centre - IRCCS, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³ Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy.
⁴ Department of Inflammation and Immunology, Humanitas Clinical and Research Centre - IRCCS, Milan, Italy.
⁵ Post-graduate Medical School of Anaesthesiology and Intensive Care, Humanitas University, Milan, Italy.
⁶ Thrombosis and Haemorrhagic Centre, Humanitas Clinical and Research Centre - IRCCS, Milan, Italy.
⁷ The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
⁸ Department of Anaesthesia and Critical Care, Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Italy.
⁹ Department of Oncology, University of Turin, Turin, Italy.

No abstract available

Keywords: Acute-phase reaction; Coronavirus infections; Inflammation; Pneumonia.

Publication types